URGN (UroGen Pharma Ltd.) Pangali Forward P/E

Simbol resmi perusahaan UroGen Pharma (URGN)

UroGen Pharma Ltd. (URGN) aims for leadership in uro-oncology through the implementation of the RTGel platform and the expanded application of Jelmyto. By comparing the company's expected P/E ratio on GURU.Markets, we see that the value 10.50 describes the current level of market expectations. Strict pharmaceutical delivery ensures drug integrity, while increasing availability in clinics triggers operating leverage, effectively boosting the business's bottom-line margins.

UroGen Pharma - Pangali Forward P/E URGN (periode 04.07.2022 - 16.11.2026)

Ringkesan rincian data analitis UroGen Pharma (URGN)

- rega saiki lan proyeksi nilai saham:
Analisis komprehensif perusahaan:URGN UroGen
Produk merek urogen.com

The forward P/E reflects the ratio of the current market share price to the expected annual net income. An increase in this metric signals an overvaluation of the asset, while a decrease indicates potential undervaluation. By analyzing the projected P/E multiple of a company, an investor assesses whether market optimism is justified. This is critical for UroGen Pharma Ltd. (URGN), as earnings depend on insurance reimbursements for hydrogel therapy. The trend of this indicator confirms the stability of the commercialization of oncology drugs.

Pesaing langsung

Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|BCAX - Pangali Forward P/E|Personalis Corp (PSNL) - Rega marang bathi mangsa ngarep|Erasca Corp - Pangali mangsa ngarep rega marang bathi|DCTH (Delcath Systems Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Y-mAbs Therapeutics, Inc. YMAB|Pangali Forward P/E AURA|Prakiraan rega marang bathi Candel Therapeutics, Inc. CADL|Pangali Forward P/E ARAY (Accuray, Inc.)|SELLAS Life Sciences - Rega marang bathi mangsa ngarep|ACTU: Prakiraan rega marang bathi|Citius Oncology, Inc. - Rasio kapitalisasi marang bathi mangsa ngarep|HURA (TuHURA Biosciences) - Prakiraan rega marang bathi|TARA: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi FATE|WHWK: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi TCRX (TScan Therapeutics Inc)|Kapitalisasi marang proyeksi bathi Champions Oncology Inc|Pangali Forward P/E XBIT (XBiotech Inc.)|Pangali mangsa ngarep rega marang bathi CVM|OS Therapies Inc. - Pangali Forward P/E|RADX - Pangali Forward P/E|ARTV: Pangali Forward P/E|ANL: Rasio kapitalisasi marang bathi mangsa ngarep|Prakiraan rega marang bathi VERU|TPST: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep xiliotx.com (XLO)|Renovaro - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Mural Oncology MURA|KAPA - Prakiraan rega marang bathi|OKUR - Rega marang bathi mangsa ngarep|GDTC - Pangali Forward P/E|Curis, Inc. (CRIS) - Rega marang bathi mangsa ngarep|Prakiraan rega marang bathi Apollomics, Inc.|Prakiraan rega marang bathi THAR|Rasio rega marang bathi mangsa ngarep ADVB (Advanced Biomed)|Prakiraan rega marang bathi GNPX (Genprex, Inc)|CLDI: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep sunshinebiopharma.com SBFM|XBIO - Prakiraan rega marang bathi|SLRX: Prakiraan rega marang bathi|Purple Biotech - Rasio kapitalisasi marang bathi mangsa ngarep|American Oncology Network (AONC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep BGNE|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|Pangali Forward P/E Ikena Oncology Inc. (IKNA)|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E